Stoke Therapeutics, Inc

(NASDAQ:STOK)

Latest On Stoke Therapeutics, Inc (STOK):

Date/Time Type Description Signal Details
2023-05-04 17:05 ESTNewsStoke Therapeutics GAAP EPS of -$0.53 beats by $0.15, revenue of $5.15M beats by $1.65MN/A
2023-05-01 14:11 ESTNewsStoke Therapeutics upgraded to neutral at BoA on Dravet candidateN/A
2023-04-26 22:19 ESTNewsStoke Therapeutics a buy at Canaccord on platform for genetic diseasesN/A
2023-04-25 22:00 ESTNewsStoke stock rises after UK regulator nod to start trial of eye disorder drugN/A
2023-03-15 17:15 ESTNewsStoke gets FDA nod to use higher dose of epilepsy drug in ongoing trialN/A
2023-03-06 19:36 ESTNewsStoke Therapeutics GAAP EPS of -$0.65 beats by $0.05, revenue of $3.27M beats by $0.41MN/A
2023-02-12 09:04 ESTNewsStoke Therapeutics Looks Unfairly ValuedN/A
2022-11-28 18:27 ESTNewsBuy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet SyndromeN/A
2022-11-14 15:38 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 beats by $0.02, revenue of $2.91M beats by $0.19MN/A
2022-11-14 15:37 ESTNewsStoke Therapeutics drops 27% after early data for anti-seizure medicineN/A
2022-08-09 08:23 ESTNewsStoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18MN/A
2022-05-10 14:29 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 misses by $0.98, revenue of $3M misses by $34.5MN/A
2022-03-10 22:22 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 misses by $0.04N/A
2022-01-31 23:13 ESTNewsStoke Therapeutics initiated Buy at Jefferies on potential of RNA platformN/A
2022-01-25 02:45 ESTNewsStoke Therapeutics (STOK) Presents At 40th Annual J.P. Morgan Virtual Healthcare ConferenceN/A
2021-12-03 21:14 ESTNewsStoke Therapeutics shares data from Phase 1/2a trial for STK-001 in Dravet syndromeN/A
2021-12-01 09:31 ESTNewsWarning: STOK is at high risk of performing badlyN/A
2021-12-01 09:31 ESTNewsStoke Therapeutics (STOK) Investor Presentation -SlideshowN/A
2021-11-23 08:45 ESTNewsStoke Therapeutics up 14% following J.P. Morgan upgrade to overweightN/A
2021-11-08 19:21 ESTNewsStoke Therapeutics EPS misses by $0.02N/A
2021-09-22 07:07 ESTNewsStoke Therapeutics posts interim results from early-stage STK-001 Dravet syndrome studyN/A
2021-08-10 12:23 ESTNewsStoke Therapeutics EPS misses by $0.12N/A
2021-03-30 13:19 ESTNewsStoke Therapeutics gets MHRA greenlight for early-stage Dravet syndrome studyN/A
2021-03-11 20:54 ESTFinancialsCompany financials have been released.Neutral
2021-03-11 12:29 ESTAnalyst RatingThe Analyst Target Price has increased from $63.75 to $65.38.Buy
2021-03-11 00:51 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-11 00:51 ESTAnalyst RatingThe Analyst Target Price has increased from $60.38 to $63.75.Buy
2021-03-11 00:51 ESTEarnings EstimateAn EPS average of -$2.12 is estimated for the 2022 year.Sell
2021-03-10 04:53 ESTFinancialsCompany financials have been released.Neutral
2021-03-07 14:56 ESTNewsSizing Up Stoke TherapeuticsN/A
2021-02-11 08:36 ESTAnalyst RatingThe Analyst Target Price has increased from $59.5 to $60.38.Neutral
2021-02-10 19:01 ESTNewsStoke cut to neutral at Wedbush seeking a ‘better entry point’N/A
2021-01-29 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $57.63 to $59.5.Neutral
2021-01-15 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $56.5 to $57.63.Neutral
2020-12-29 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $54.13 to $56.5.Neutral
2020-12-16 13:07 ESTAnalyst RatingThe Analyst Target Price has increased from $49.13 to $54.13.Neutral
2020-12-14 08:52 ESTAnalyst RatingThe Analyst Target Price has increased from $48.13 to $49.13.Neutral
2020-12-14 08:12 ESTNewsStoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market CapN/A
2020-11-26 21:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-20 03:45 ESTNewsStoke Therapeutics prices $97.5M public offeringN/A
2020-11-19 00:23 ESTNewsStoke Therapeutics -2.7% AH, proposes public offeringN/A
2020-11-17 05:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:28 ESTAnalyst RatingThe Analyst Target Price has increased from $47.13 to $48.13.Buy
2020-11-14 21:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 13:26 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-13 13:26 ESTAnalyst RatingThe Analyst Target Price has increased from $41.5 to $47.13.Buy
2020-11-13 10:25 ESTNewsStoke Therapeutics EPS in-lineN/A
2020-11-08 00:59 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:14 ESTFinancialsCompany financials have been released.Neutral
2020-11-04 18:01 ESTInsider TradeHuw M. Nash has directly disposed of 2,536 shares and currently holds 0 shares.Sell

About Stoke Therapeutics, Inc (STOK):

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

STOK Quotes by TradingView

See Advanced Chart

General

  • Name Stoke Therapeutics, Inc
  • Symbol STOK
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 79
  • Fiscal Year EndDecember
  • IPO Date2019-06-19
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.stoketherapeutics.com
View More

Valuation

  • Trailing PE 21.65
  • Price/Book (Most Recent Quarter) 6.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.80
  • Next Year EPS Estimate -$2.10
  • Next Quarter EPS Estimate -$0.44
  • Return on Assets -13%
  • Return on Equity -20%
  • Earnings Per Share -$11.44
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.78 billion
  • EBITDA -22302000
  • PE Ratio -7.4
  • Analyst Target Price $65.38
  • Book Value Per Share $7.14
View More

Share Statistics

  • Shares Outstanding 36.66 million
  • Shares Float 12.64 million
  • % Held by Insiders 170%
  • % Held by Institutions 98.06%
  • Shares Short 3.3 million
  • Shares Short Prior Month 3.37 million
  • Short Ratio 27.54
  • Short % of Float 21%
  • Short % of Shares Outstanding 9%
View More

Technicals

  • 52 Week High $71.58
  • 52 Week Low $17.55
  • 50 Day Moving Average 58.62
  • 200 Day Moving Average 48.97
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Stoke Therapeutics, Inc (STOK) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Stoke Therapeutics, Inc (STOK) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$N/A-$0.42-$0.420.92%
2020-09-302020-11-12$N/A-$0.41-$0.434.58%
2020-06-302020-08-10$N/A-$0.39-$0.36-8.33%
2020-03-312020-05-15$N/A-$0.34-$0.378.87%
2019-12-312020-03-23$N/A-$0.09-$0.3069.63%
2019-09-302019-11-12$N/A-$0.26-$0.285.83%
2019-06-302019-08-14$N/A-$1.54-$1.635.39%

Stoke Therapeutics, Inc (STOK) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 8.9 million N/A N/A 7.22 million 7.09 million
Income Before Tax -14.56 million N/A N/A -11.04 million -10.16 million
Selling General Administrative 5.68 million N/A N/A 4.52 million 3.98 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -14.35 million N/A N/A -11.54 million -11.07 million
Operating Income -14.59 million N/A N/A -11.74 million -11.07 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net 15000 N/A N/A 22000 908000
Net Income From Continuing Operations -14.56 million N/A N/A -11.04 million -10.16 million
Net Income Applicable to Common Shares -14.56 million -13.68 million -12.96 million N/A -10.16 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -269000 -81000 -610000 N/A N/A
Change to Liabilities 610000 N/A N/A N/A N/A
Total Cash Flow from Investing Activities -269000 N/A N/A N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 673000 369000 198000 N/A N/A
Change to Operating Activities -80000 N/A N/A N/A N/A
Change in Cash -10.47 million -9.36 million -11.18 million N/A N/A
Total Cash from Operating Activities -10.87 million -9.65 million -10.77 million N/A N/A
Depreciation 234000 224000 193000 N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities -360000 N/A N/A N/A N/A
Change to Net Income 2.05 million N/A N/A N/A N/A
Capital Expenditures 269000 81000 610000 N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 11.85 million N/A N/A 6.5 million 4.32 million
Total Stockholder Equity 286.08 million N/A N/A 214.34 million 224.43 million
Other Current Liabilities N/A N/A N/A 54000 N/A
Total Assets 297.93 million N/A N/A 220.84 million 228.75 million
Common Stock 4000 3000 3000 N/A 3000
Other Current Assets 6.62 million 378000 N/A N/A N/A
Retained Earnings -110.28 million -95.72 million -82.03 million -69.07 million -58.04 million
Other Liabilities N/A 665000 1.01 million N/A 221000
Other Assets N/A 205000 205000 N/A 205000
Cash 287.31 million N/A N/A 211.29 million 222.47 million
Total Current Liabilities 11.43 million 6.74 million N/A 5.46 million 4.1 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 2.68 million 4.27 million 4.47 million N/A 2.51 million
Total Current Assets 293.93 million 195.46 million N/A 215.77 million 226.03 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 286.08 million 192.54 million 203.4 million N/A 224.43 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 11.43 million 1.1 million N/A 1.78 million 751000

Stoke Therapeutics, Inc (STOK) Chart:

Stoke Therapeutics, Inc (STOK) News:

Below you will find a list of latest news for Stoke Therapeutics, Inc (STOK) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Stoke Therapeutics, Inc (STOK) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-11-212.521.76CALL0 7635.14TRUE00
2025-11-21519.28CALL0 7444.93TRUE00
2025-11-217.54.2CALL0 0343.37TRUE00
2025-11-211021CALL0 22274.21TRUE00
2025-11-2112.521.85CALL0 9221.72TRUE00
2025-11-211512.48CALL0 25179.29TRUE00
2025-11-2117.57.5CALL0 31171.64TRUE00
2025-11-212014.9CALL0 17104.25TRUE00
2025-11-2122.57.32CALL1 8108.46TRUE7.320
2025-11-21258.3CALL0 5180116.98TRUE00
2025-11-21303.27CALL23 193115.2TRUE-1.06-0.24
2025-11-21351.15CALL137 92098.49FALSE-0.98-0.46
2025-11-21400.75CALL19 657118.01FALSE-0.4-0.35
2025-11-21450.5CALL0 48227.78FALSE00
2025-11-21500CALL0 0348FALSE00
2025-11-212.50PUT0 10990.94FALSE00
2025-11-2150PUT0 0661.86FALSE00
2025-11-217.50.9PUT0 13508.26FALSE00
2025-11-21100.1PUT0 15290.53FALSE00
2025-11-2112.50.05PUT0 36263.38FALSE00
2025-11-21150.12PUT0 30192.92FALSE00
2025-11-2117.50.1PUT0 12484.1FALSE00
2025-11-21200.35PUT0 367408.59FALSE00
2025-11-2122.50.9PUT38 6142.07FALSE0.90
2025-11-21251.38PUT8 49130.31FALSE1.380
2025-11-21303.62PUT5 159131.53FALSE3.620
2025-11-21357.1PUT1 55139.57TRUE7.10
2025-11-21408.15PUT0 14145.08TRUE00
2025-11-21450PUT0 0153.66TRUE00
2025-11-21500PUT0 0162.68TRUE00
2025-12-19150CALL0 0157.7TRUE00
2025-12-1917.50CALL0 0128.06TRUE00
2025-12-19200CALL0 0126.11TRUE00
2025-12-1922.50CALL0 099.72TRUE00
2025-12-19259.55CALL0 13105.72TRUE00
2025-12-19305.95CALL0 5122.17TRUE00
2025-12-19352.9CALL12 37105.76FALSE2.90
2025-12-19402.3CALL0 6293.41FALSE00
2025-12-19451.5CALL0 3204.7FALSE00
2025-12-19500CALL0 0224.07FALSE00
2025-12-19150PUT0 0372.37FALSE00
2025-12-1917.50PUT0 0313.52FALSE00
2025-12-19200.75PUT0 2264.74FALSE00
2025-12-1922.50PUT0 0222.58FALSE00
2025-12-19252.17PUT8 0108.31FALSE2.170
2025-12-19302.85PUT0 2106.58FALSE00
2025-12-19357.7PUT1 1105.87TRUE7.70
2025-12-19400PUT0 0102.83TRUE00
2025-12-19450PUT0 0118.33TRUE00
2025-12-19500PUT0 0104.4TRUE00
2026-02-202.59.9CALL0 2263.79TRUE00
2026-02-20525.2CALL1 29167.82TRUE-1.1-0.04
2026-02-207.527CALL0 7163.06TRUE00
2026-02-201022.45CALL0 17152.45TRUE00
2026-02-2012.519.2CALL0 74123.12TRUE00
2026-02-201519.1CALL0 34121.83TRUE00
2026-02-2017.516CALL0 69117.05TRUE00
2026-02-202019.5CALL0 84107.02TRUE00
2026-02-2022.514.1CALL0 5891.89TRUE00
2026-02-20258.5CALL1 6391.22TRUE8.50
2026-02-20307.5CALL0 2389.24TRUE00
2026-02-20355.25CALL0 2386.09FALSE00
2026-02-20404.37CALL0 1089.81FALSE00
2026-02-20452.2CALL8 10690.37FALSE-0.8-0.27
2026-02-20502CALL0 1146.58FALSE00
2026-02-202.50PUT0 0422.72FALSE00
2026-02-2050.15PUT0 1282.45FALSE00
2026-02-207.50.28PUT0 7217.08FALSE00
2026-02-20100.7PUT0 4365.29FALSE00
2026-02-2012.51PUT0 9295.91FALSE00
2026-02-20151.8PUT0 43246.34FALSE00
2026-02-2017.52.5PUT0 2207.56FALSE00
2026-02-20200PUT0 0119.73FALSE00
2026-02-2022.50PUT0 0102.47FALSE00
2026-02-20250PUT0 095.31FALSE00
2026-02-20305.5PUT0 494.98FALSE00
2026-02-20350PUT0 099TRUE00
2026-02-20400PUT0 095.83TRUE00
2026-02-20450PUT0 099.03TRUE00
2026-02-20500PUT0 098.05TRUE00
2026-05-1512.515.7CALL0 10109.56TRUE00
2026-05-151513.82CALL0 1103.64TRUE00
2026-05-1517.50CALL0 0107.01TRUE00
2026-05-152010.12CALL0 188.16TRUE00
2026-05-1522.513.2CALL0 57100.12TRUE00
2026-05-152510.14CALL2 790.29TRUE10.140
2026-05-15308.2CALL2 1592.64TRUE8.20
2026-05-15357.2CALL1 70100.14FALSE7.20
2026-05-15405.6CALL2 1496.48FALSE5.60
2026-05-15455.5CALL0 795.53FALSE00
2026-05-15503.9CALL0 395.01FALSE00
2026-05-1512.50.9PUT0 3224.76FALSE00
2026-05-15151.35PUT0 12187.23FALSE00
2026-05-1517.52PUT0 2110.65FALSE00
2026-05-15202.05PUT0 2101.22FALSE00
2026-05-1522.53.9PUT11 297.17FALSE3.90
2026-05-15254.3PUT0 11107.26FALSE00
2026-05-15306.5PUT0 491.14FALSE00
2026-05-15357.3PUT0 1100.05TRUE00
2026-05-154010.1PUT0 199.93TRUE00
2026-05-154515.7PUT0 189.57TRUE00
2026-05-15500PUT0 090.44TRUE00

Latest STOK Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST13$10.47
Jun 13, 2022 7:59 PM EST60$10.47
Jun 13, 2022 7:59 PM EST20$10.47
Jun 13, 2022 7:59 PM EST41$10.47
Jun 13, 2022 7:59 PM EST15$10.47

Stoke Therapeutics, Inc (STOK) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2019-04-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019007260/0000000000-19-007260-index.htm
2019-05-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019008485/0000000000-19-008485-index.htm
2019-06-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019009270/0000000000-19-009270-index.htm
2019-06-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019009719/0000000000-19-009719-index.htm
2020-07-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000020006449/0000000000-20-006449-index.htm
2019-07-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000092963819000658/0000929638-19-000658-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000092963820000333/0000929638-20-000333-index.htm
2019-03-26DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319002845/0000950123-19-002845-index.htm
2019-04-30DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319003688/0000950123-19-003688-index.htm
2019-04-30DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319003690/0000950123-19-003690-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000110465920021017/0001104659-20-021017-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000114420419031374/0001144204-19-031374-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000114420419032095/0001144204-19-032095-index.htm
2019-05-23S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519155301/0001193125-19-155301-index.htm
2019-05-23CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519155321/0001193125-19-155321-index.htm
2019-06-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519163789/0001193125-19-163789-index.htm
2019-06-07S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519167576/0001193125-19-167576-index.htm
2019-06-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519167579/0001193125-19-167579-index.htm
2019-06-118-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519170268/0001193125-19-170268-index.htm
2019-06-12S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519171310/0001193125-19-171310-index.htm
2019-06-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519171314/0001193125-19-171314-index.htm
2019-06-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519173255/0001193125-19-173255-index.htm
2019-06-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519173266/0001193125-19-173266-index.htm
2019-06-19S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1623526/000119312519175848/0001193125-19-175848-index.htm
2019-06-18S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519175863/0001193125-19-175863-index.htm
2019-06-19424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519176488/0001193125-19-176488-index.htm
2019-07-01SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1623526/000119312519186323/0001193125-19-186323-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312519220567/0001193125-19-220567-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312519308649/0001193125-19-308649-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520005877/0001193125-20-005877-index.htm
2020-03-23S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1623526/000119312520082470/0001193125-20-082470-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520108110/0001193125-20-108110-index.htm
2020-04-21DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1623526/000119312520113542/0001193125-20-113542-index.htm
2020-04-21DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1623526/000119312520113561/0001193125-20-113561-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520139879/0001193125-20-139879-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520160684/0001193125-20-160684-index.htm
2020-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520189990/0001193125-20-189990-index.htm
2020-07-10S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312520191098/0001193125-20-191098-index.htm
2020-07-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312520193961/0001193125-20-193961-index.htm
2020-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520221818/0001193125-20-221818-index.htm
2020-08-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520226962/0001193125-20-226962-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520265127/0001193125-20-265127-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021312/0001209191-20-021312-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021314/0001209191-20-021314-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021317/0001209191-20-021317-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021319/0001209191-20-021319-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021321/0001209191-20-021321-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021322/0001209191-20-021322-index.htm
2020-04-153/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024540/0001209191-20-024540-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024543/0001209191-20-024543-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-05-264/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032142/0001209191-20-032142-index.htm
2020-05-264/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032146/0001209191-20-032146-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034721/0001209191-20-034721-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034723/0001209191-20-034723-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034729/0001209191-20-034729-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034731/0001209191-20-034731-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034732/0001209191-20-034732-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034735/0001209191-20-034735-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034737/0001209191-20-034737-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042004/0001209191-20-042004-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042007/0001209191-20-042007-index.htm
2020-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-08-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-10-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-10-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-06-13CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1623526/000135445719000309/0001354457-19-000309-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009407/0001493152-19-009407-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009471/0001493152-19-009471-index.htm
2019-06-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009851/0001493152-19-009851-index.htm
2019-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219014877/0001493152-19-014877-index.htm
2019-11-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016566/0001493152-19-016566-index.htm
2019-11-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016926/0001493152-19-016926-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000149315220002386/0001493152-20-002386-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459019032126/0001564590-19-032126-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459019042621/0001564590-19-042621-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459019042891/0001564590-19-042891-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020012112/0001564590-20-012112-index.htm
2020-03-2310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1623526/000156459020012202/0001564590-20-012202-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020025636/0001564590-20-025636-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459020025637/0001564590-20-025637-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020038587/0001564590-20-038587-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459020038905/0001564590-20-038905-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013623/0001567619-19-013623-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013624/0001567619-19-013624-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013625/0001567619-19-013625-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013626/0001567619-19-013626-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013627/0001567619-19-013627-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013628/0001567619-19-013628-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013629/0001567619-19-013629-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013630/0001567619-19-013630-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013631/0001567619-19-013631-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013632/0001567619-19-013632-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013633/0001567619-19-013633-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013662/0001567619-19-013662-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/0001567619-19-013838-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/0001567619-19-013840-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018220/0001567619-19-018220-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018221/0001567619-19-018221-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018222/0001567619-19-018222-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018223/0001567619-19-018223-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018224/0001567619-19-018224-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018225/0001567619-19-018225-index.htm
2019-11-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919021770/0001567619-19-021770-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919021771/0001567619-19-021771-index.htm
2014-11-24DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000162352614000001/0001623526-14-000001-index.htm
2018-11-02DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000162352618000002/0001623526-18-000002-index.htm
2019-06-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1623526/999999999519001367/9999999995-19-001367-index.htm
2020-07-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1623526/999999999520001866/9999999995-20-001866-index.htm
2019-06-03SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1623526/999999999719005333/9999999997-19-005333-index.htm
2019-06-13SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1623526/999999999719005455/9999999997-19-005455-index.htm

Stoke Therapeutics, Inc (STOK) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Stoke Therapeutics, Inc (STOK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 170%
Institutional Ownership: 9806%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-03-02Huw M. NashCOO & CBOSell15,995.0026.37421,852.130.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-06-01Huw M. NashCOO & CBOSell500.0027.4813,742.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-07-01Huw M. NashCOO & CBOSell3,800.0023.1587,967.720.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-07-07Huw M. NashCOO & CBOSell913.0022.4120,456.860.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042004/0001209191-20-042004-index.htm
2020-07-16Huw M. NashCOO & CBOSell1,900.0025.0647,614.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-08-03Huw M. NashCOO & CBOSell5,700.0024.73140,943.330.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-08-28Huw M. NashCOO & CBOSell2,081.0030.0062,430.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-09-01Huw M. NashCOO & CBOSell700.0028.7120,097.630.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-09-08Huw M. NashCOO & CBOSell30,718.0030.00921,540.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-09-09Huw M. NashCOO & CBOSell17,201.0030.00516,030.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-10-01Huw M. NashCOO & CBOSell2,300.0034.8680,182.600.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-02Huw M. NashCOO & CBOSell2,536.0037.9896,324.890.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-07-07Robin A. WalkerChief Legal Officer, CCO & SecSell941.0022.5021,172.500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042007/0001209191-20-042007-index.htm
2020-11-02Stephen J TulipanoCFOSell14,445.0037.86546,909.371,002.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-06-01Barry TichoChief Medical OfficerBuy131,147.000.6078,688.20131,147.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-03-31Gene LiauEVP Research & Preclinical DevBuy7,500.000.604,500.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-05-22Gene LiauEVP Research & Preclinical DevSell7,500.0030.00225,000.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell1,230.0027.4833,801.5113,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-13Gene LiauEVP Research & Preclinical DevSell1,649.0040.0065,960.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-10-16Gene LiauEVP Research & Preclinical DevSell5,851.0040.00234,041.7613,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevSell7,225.0038.42277,585.9513,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell7,875.0026.91211,920.9814,730.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-13Gene LiauEVP Research & Preclinical DevBuy1,649.000.60989.4015,149.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-11-02Stephen J TulipanoCFOSell20,155.0036.79741,448.0315,447.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-03-02Huw M. NashCOO & CBOSell33,148.0025.66850,697.0115,995.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2019-06-21Apple Tree Partners IV, L.P.10% Share HolderBuy1,388,889.0018.0025,000,002.0016,786,713.00https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/0001567619-19-013838-index.htm
2019-06-21Seth Loring HarrisonDirectorBuy1,388,889.0018.0025,000,002.0016,786,713.00https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/0001567619-19-013840-index.htm
2020-11-04Stephen J TulipanoCFOSell16,941.0040.03678,085.5516,929.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-09-09Huw M. NashCOO & CBOBuy17,201.002.1937,670.1917,201.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-06-01Barry TichoChief Medical OfficerSell365.0027.9810,212.70172,662.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-01Barry TichoChief Medical OfficerSell1,000.0027.1727,174.00173,027.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-01Barry TichoChief Medical OfficerBuy42,880.002.1993,907.20174,027.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-07-16Huw M. NashCOO & CBOBuy1,900.002.194,161.001,900.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-10-16Gene LiauEVP Research & Preclinical DevBuy5,851.000.603,510.6019,351.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevSell24,775.0037.64932,578.0720,725.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-08-28Huw M. NashCOO & CBOBuy2,081.002.194,557.392,081.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-05-22Gene LiauEVP Research & Preclinical DevBuy7,500.000.604,500.0021,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-01Huw M. NashCOO & CBOBuy2,107.002.194,614.332,107.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell10,895.0025.82281,314.3522,605.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-01Huw M. NashCOO & CBOSell3,400.0034.33116,717.922,300.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-03Stephen J TulipanoCFOBuy1,732.004.487,759.362,334.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-02Huw M. NashCOO & CBOSell3,164.0036.59115,785.002,536.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-09-08Huw M. NashCOO & CBOBuy30,718.002.1967,272.4230,718.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevBuy20,000.002.1943,800.0033,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2019-06-19RTW INVESTMENTS, LP10% Share HolderBuy555,556.0018.0010,000,008.003,355,466.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219009471/0001493152-19-009471-index.htm
2020-11-04Stephen J TulipanoCFOBuy33,268.004.48149,040.6433,870.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-10-01RTW INVESTMENTS, LP10% Share HolderBuy31,560.0021.96693,029.203,387,026.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219014877/0001493152-19-014877-index.htm
2019-10-30RTW INVESTMENTS, LP10% Share HolderBuy41,438.0028.791,193,004.163,428,464.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-10-31RTW INVESTMENTS, LP10% Share HolderBuy18,747.0028.15527,658.693,447,211.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-01RTW INVESTMENTS, LP10% Share HolderBuy8,598.0028.61245,950.093,455,809.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-08RTW INVESTMENTS, LP10% Share HolderSell16,434.0028.70471,631.153,544,248.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016926/0001493152-19-016926-index.htm
2020-11-02Stephen J TulipanoCFOBuy35,000.004.48156,800.0035,602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-11-04RTW INVESTMENTS, LP10% Share HolderBuy104,873.0029.243,066,843.093,560,682.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016566/0001493152-19-016566-index.htm
2020-07-01Huw M. NashCOO & CBOBuy3,800.002.198,322.003,800.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevBuy30,497.000.6018,298.2043,997.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevBuy1,503.002.193,291.5745,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-03-02Huw M. NashCOO & CBOBuy42,779.002.1993,686.0149,103.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-06-01Huw M. NashCOO & CBOSell1,607.0027.0843,521.26500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2019-12-16Edward M. MD KayeCEOBuy50,000.000.6030,000.0050,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024543/0001209191-20-024543-index.htm
2020-08-03Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-09-01Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-10-01Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-02Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-11-04Stephen J TulipanoCFOSell11,111.0041.42460,214.295,818.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-12-20Gene LiauEVP Research & Preclinical DevBuy6,000.000.603,600.006,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-11-02Stephen J TulipanoCFOSell400.0038.4415,374.00602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-03Stephen J TulipanoCFOSell1,732.0039.8468,997.51602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-04Stephen J TulipanoCFOSell5,216.0041.97218,909.78602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-03-02Huw M. NashCOO & CBOBuy6,324.000.402,529.606,324.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-09-01Huw M. NashCOO & CBOSell5,000.0027.60138,015.00700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm